|
Dr. Mills has over twenty-five years of experience in biomedical research, corporate management and venture investing. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. He has served Sanderling's portfolio companies as Chairman, Chief Executive Officer, Director, and/or management team member.
Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific in 1997. From July 1994 to July 1997, he was a director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates.
Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder. | 